Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jan 21, 2016
DelveInsight, the leading market research and consulting company has added new report “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016” to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise pro...
Read More...
Jan 21, 2016
DelveInsight, the leading market research and consulting company has added new report “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016”to its portfolio. Reports Highlights: · CAR-T cell Therapy Pipeline scenario · Collaborations &...
Read More...
Jan 13, 2016
DelveInsight, the leading market research and consulting company has added new report Zemplar -Drug Insights, 2016 to its portfolio. With this launch DelveInsight now has 400+ Reports on Drug Insight. In addition to this our research expertise provides our clients with up to date information of market till date orde...
Read More...
Jan 12, 2016
DelveInsight, the leading market research and consulting company has added new report Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clien...
Read More...
Jan 12, 2016
DelveInsight, the leading market research and consulting company has added new report Peripheral Lung Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date inf...
Read More...
Jan 12, 2016
DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on indication, mechanism of actions, drugs, Global API Manufacturers and specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1, CART and Antibody Drug conjugates. After tremendous success last yea...
Read More...
Nov 10, 2015
In the years since the discovery of RNA interference, researchers have found that this process is far more widespread than we might expect, and that small pieces of RNA play many functional roles. Small (or short) interfering RNA (siRNA) is the most commonly used RNA interference (RNAi) tool for inducing short-term ...
Read More...
Sep 01, 2015
Introduction A disease that has not been adopted by the pharmaceutical industry because it provides little financial incentive for the private sector to make and market new medications to treat or prevent it. An orphan disease may be a rare disease or a common disease that has been ignored because it is far more pr...
Read More...
Jul 24, 2015
In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis is one such adverse effect that results in ulceration in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of...
Read More...
Jun 03, 2015
Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed! Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that i...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper